Ra Pharmaceuticals (NASDAQ:RARX) Announces Earnings Results

Ra Pharmaceuticals (NASDAQ:RARX) announced its earnings results on Thursday. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.05), Fidelity Earnings reports. The business had revenue of $3.00 million during the quarter.

Shares of RARX stock traded up $0.05 during mid-day trading on Friday, hitting $46.82. 413,300 shares of the company’s stock were exchanged, compared to its average volume of 652,991. Ra Pharmaceuticals has a fifty-two week low of $11.27 and a fifty-two week high of $47.35. The stock has a 50-day simple moving average of $37.22 and a two-hundred day simple moving average of $29.56. The company has a quick ratio of 15.30, a current ratio of 15.30 and a debt-to-equity ratio of 0.02. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -22.73 and a beta of 1.55.

RARX has been the topic of a number of analyst reports. Zacks Investment Research cut Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 17th. SunTrust Banks cut Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 14th. BidaskClub cut Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 10th. ValuEngine upgraded Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Finally, Robert W. Baird cut Ra Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $48.00 price objective on the stock. in a report on Thursday, October 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $45.36.

In related news, insider Ramin Farzaneh-Far sold 10,595 shares of Ra Pharmaceuticals stock in a transaction on Monday, September 16th. The stock was sold at an average price of $25.26, for a total value of $267,629.70. Following the transaction, the insider now owns 8,521 shares in the company, valued at $215,240.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alonso Ricardo sold 2,285 shares of Ra Pharmaceuticals stock in a transaction on Thursday, October 17th. The shares were sold at an average price of $46.70, for a total value of $106,709.50. Following the completion of the transaction, the insider now owns 6,858 shares in the company, valued at approximately $320,268.60. The disclosure for this sale can be found here. Insiders have sold 43,475 shares of company stock worth $1,402,939 in the last 90 days. Insiders own 4.30% of the company’s stock.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Recommended Story: How does a margin account work?

Earnings History for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.